atm kinase inhibitor azd0156

Drug Overview

AZD0156 is an innovative, experimental medication being developed to fight advanced cancers. In the medical community, it is classified as a Targeted Therapy or a “Smart Drug.” This is because it does not attack all cells like traditional chemotherapy. Instead, it targets a specific protein that cancer cells use to repair their own DNA when it becomes damaged.

Currently, atm kinase inhibitor azd0156 is an investigational drug. This means it is not yet available at your local pharmacy and is being used only in clinical trials. Researchers are testing it to see how well it works on its own and when combined with other cancer-fighting medications.

• Generic Name: AZD0156
• US Brand Names: None (Currently investigational)
• Drug Class: ATM (Ataxia Telangiectasia Mutated) Kinase Inhibitor
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Not FDA Approved; currently in Phase I and Phase II clinical trials.
  
  Explore targeted therapy using the atm kinase inhibitor azd0156. Trust our medical experts to design the best personalized care plan for you.

What Is It and How Does It Work? (Mechanism of Action)

To understand how AZD0156 works, it is helpful to think of a cancer cell as a building that is constantly under construction. In this building, the DNA acts as the blueprint. Every day, the blueprints get “tears” or breaks. In cancer cells, these breaks happen even faster.

The body has a natural repair crew to fix these breaks. A key leader of this repair crew is a protein called ATM kinase. When a serious break happens in the DNA (called a double-strand break), the ATM protein sends out a loud alarm signal. This signal tells the cell to stop dividing and start fixing the damage.

How AZD0156 stops the repair:

AZD0156 is designed to be a “wrench in the gears.” It is a potent and highly selective inhibitor of the ATM kinase. When a patient takes this medication, the drug enters the cancer cell and binds directly to the ATM protein. This blocks the alarm signal.

At the molecular level, this prevents the activation of signaling pathways like p53, CHK2, and BRCA1. Because the “alarm” is never pulled, the cancer cell continues to try to divide with broken DNA. This leads to a massive buildup of genetic errors. Eventually, the cell realizes it is too damaged to function and triggers a self-destruct sequence called apoptosis.

By blocking the cell’s ability to repair itself, AZD0156 makes the cancer much more vulnerable, especially when used with other treatments like radiation or PARP inhibitors that cause even more DNA damage.

FDA Approved Clinical Indications

As of early 2026, AZD0156 does not have official FDA approval for general public use. It is currently being studied in clinical trials for the following:

Oncological Uses (Investigational):

• Advanced Solid Tumors: For patients with tumors that have spread (metastatic) and have not responded to other treatments.
• Triple-Negative Breast Cancer: Often studied in combination with other targeted therapies.
• Gastric (Stomach) Cancer: Specifically being tested alongside chemotherapy.
• Ovarian and Prostate Cancer: Investigated for use in patients with specific genetic mutations (like ATM or BRCA mutations).

Non-oncological Uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because AZD0156 is in the testing phase, the exact “best” dose is still being determined by doctors. The following table shows common protocols seen in recent clinical research.

Dose Adjustments

• Hepatic (Liver) Insufficiency: Since the liver processes this medication, doctors monitor liver enzymes closely. If liver tests become too high, the dose is usually lowered or paused.
• Renal (Kidney) Insufficiency: Current data is limited; however, patients with severe kidney disease are monitored for signs of drug buildup in the blood.

Clinical Efficacy and Research Results

Clinical data from 2020 through 2025 has shown that AZD0156 is especially effective when used as a “force multiplier” with other drugs.

• Combination with PARP Inhibitors: In trials combining AZD0156 with olaparib (Lynparza), researchers found that the combination could shrink tumors even in patients whose cancer had become resistant to other treatments. Early data showed a “Disease Control Rate” of over 55% in certain resistant breast cancer groups.
• Tumor Shrinkage: In Phase I/II dose-escalation studies, some patients with gastric cancer showed a significant reduction in tumor size (over 30% reduction) when the drug was added to standard chemotherapy.
• Numerical Trends: While long-term survival rates are still being calculated, early reports suggest that adding AZD0156 to other therapies can extend “Progression-Free Survival” (the time a patient lives without the cancer getting worse) by several months compared to standard care alone.

Safety Profile and Side Effects

Because AZD0156 interferes with DNA repair, it can affect healthy cells that divide quickly, such as blood cells and the lining of the stomach.

Warning Information

There is currently no Black Box Warning for AZD0156, as it has not yet reached full commercial approval.

Common Side Effects (>10%)

• Nausea and Vomiting: Usually mild and can be managed with other medicines.
• Fatigue: A general feeling of being very tired or having low energy.
• Anemia: A decrease in red blood cells, which can cause shortness of breath.
• Neutropenia: A drop in white blood cells, which can make it easier to get an infection.
• Decreased Appetite.

Serious Adverse Events

• Bone Marrow Suppression: A dangerous drop in blood counts that may require a transfusion.
• Pneumonitis: Rare but serious inflammation of the lungs.
• Hepatotoxicity: Significant stress on the liver (detected through blood tests).

Management Strategies

• For Low Blood Counts: Doctors perform weekly blood draws. If counts drop too low, they may give “growth factor” shots or pause the medication.
• For Nausea: Patients are encouraged to take the medication with a light snack and may be given anti-nausea pills to use at home.

Research Areas

AZD0156 is a major focus in the field of DNA Damage Response (DDR). Current research is exploring how to use this drug in “Synthetic Lethality” strategies. This means finding cancers that are already weak in one repair area and using AZD0156 to knock out their last remaining backup repair system. There is also new research looking into whether AZD0156 can be used with Immunotherapy. Scientists believe that by causing more DNA damage in the tumor, the cancer might become “visible” to the immune system, making it easier for the body to attack.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Genetic Profiling: To see if the tumor has specific mutations (like ATM or BRCA) that make it more likely to respond to the drug.
• Complete Blood Count (CBC): To establish your starting levels of red and white blood cells.
• Liver Function Test: To ensure the liver is healthy enough for the medication.

Precautions During Treatment

• Infection Risk: Wash your hands often and avoid people who are sick, especially if your white blood cell counts are low.
• Sun Sensitivity: Some targeted therapies make the skin easier to burn. Wear sunscreen and hats when outside.

“Do’s and Don’ts”

• DO take the tablets at the same time each day to keep a steady amount of medicine in your body.
• DO report any new cough or fever to your medical team immediately.
• DON’T stop taking the medication without talking to your doctor, as this could allow the cancer to grow back quickly.
• DON’T eat grapefruit or drink grapefruit juice, as it can interfere with how the drug is absorbed.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. AZD0156 is an investigational drug and is not currently FDA-approved for commercial use. It should only be used under the supervision of a qualified oncologist within a clinical trial setting. Always consult your healthcare provider regarding any questions about a medical condition or treatment. As research is ongoing, ensure you discuss the most up-to-date data with your oncology team.